These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 2903110)
1. Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis. Mulder CJ; Tytgat GN; Weterman IT; Dekker W; Blok P; Schrijver M; van der Heide H Gastroenterology; 1988 Dec; 95(6):1449-53. PubMed ID: 2903110 [TBL] [Abstract][Full Text] [Related]
2. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Feagan BG; Macdonald JK Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889 [TBL] [Abstract][Full Text] [Related]
3. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. The Mesalamine Study Group. Ann Intern Med; 1996 Jan; 124(2):204-11. PubMed ID: 8533995 [TBL] [Abstract][Full Text] [Related]
4. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. Rachmilewitz D BMJ; 1989 Jan; 298(6666):82-6. PubMed ID: 2563951 [TBL] [Abstract][Full Text] [Related]
5. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Hanauer S; Schwartz J; Robinson M; Roufail W; Arora S; Cello J; Safdi M Am J Gastroenterol; 1993 Aug; 88(8):1188-97. PubMed ID: 8338086 [TBL] [Abstract][Full Text] [Related]
6. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Riley SA; Mani V; Goodman MJ; Herd ME; Dutt S; Turnberg LA Gastroenterology; 1988 Jun; 94(6):1383-9. PubMed ID: 2896139 [TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. Miner P; Hanauer S; Robinson M; Schwartz J; Arora S Dig Dis Sci; 1995 Feb; 40(2):296-304. PubMed ID: 7851193 [TBL] [Abstract][Full Text] [Related]
8. Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid. Dew MJ; Hughes P; Harries AD; Williams G; Evans BK; Rhodes J Br Med J (Clin Res Ed); 1982 Oct; 285(6347):1012. PubMed ID: 6127137 [No Abstract] [Full Text] [Related]
9. Comparable efficacy of oral 5-aminosalicylic acid (Mesasal) and sulfasalazine in maintaining ulcerative colitis in remission. Eliakim R; Wengrower D; Ligumsky M; Rachmilewitz D Isr J Med Sci; 1990 Jan; 26(1):47-9. PubMed ID: 1968895 [No Abstract] [Full Text] [Related]
10. Treatment of ulcerative colitis with oral 5-aminosalicylic acid including patients with adverse reactions to sulfasalazine. Habal FM; Greenberg GR Am J Gastroenterol; 1988 Jan; 83(1):15-9. PubMed ID: 2892391 [TBL] [Abstract][Full Text] [Related]
11. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Sutherland LR; May GR; Shaffer EA Ann Intern Med; 1993 Apr; 118(7):540-9. PubMed ID: 8095128 [TBL] [Abstract][Full Text] [Related]
12. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Sninsky CA; Cort DH; Shanahan F; Powers BJ; Sessions JT; Pruitt RE; Jacobs WH; Lo SK; Targan SR; Cerda JJ Ann Intern Med; 1991 Sep; 115(5):350-5. PubMed ID: 1863024 [TBL] [Abstract][Full Text] [Related]
13. Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: a prospective, double-blind, randomized multicenter study. The Ulcerative Colitis Multicenter Study Group. Rijk MC; van Lier HJ; van Tongeren JH Am J Gastroenterol; 1992 Apr; 87(4):438-42. PubMed ID: 1348159 [TBL] [Abstract][Full Text] [Related]
14. Coated oral 5-aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. A double-blind study. Ardizzone S; Petrillo M; Molteni P; Desideri S; Bianchi Porro G J Clin Gastroenterol; 1995 Dec; 21(4):287-9. PubMed ID: 8583101 [TBL] [Abstract][Full Text] [Related]
15. Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group. Fockens P; Mulder CJ; Tytgat GN; Blok P; Ferwerda J; Meuwissen SG; Tuynman HA; Dekker W; Gasthuis K; van Hees PA Eur J Gastroenterol Hepatol; 1995 Nov; 7(11):1025-30. PubMed ID: 8680900 [TBL] [Abstract][Full Text] [Related]